Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial

医学 射血分数 心力衰竭 艾普沃思嗜睡量表 呼吸 随机对照试验 临床终点 心脏病学 多导睡眠图 内科学 麻醉 物理疗法 呼吸暂停
作者
Thomas Douglas Bradley,Alexander G. Logan,Geraldo Lorenzi‐Filho,R. John Kimoff,Joaquín Durán‐Cantolla,Michael E. Arzt,Stefania Redolfi,Gianfranco Parati,Takatoshi Kasai,Mark E. Dunlap,Diego Delgado,Shoichiro Yatsu,Adriana Bertolami,Rodrigo Pinto Pedrosa,GEORGE A. TOMLINSON,José María Marín,Claudio Tantucci,John S. Floras
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:12 (2): 153-166 被引量:121
标识
DOI:10.1016/s2213-2600(23)00374-0
摘要

Summary

Background

In patients with heart failure and reduced ejection fraction, sleep-disordered breathing, comprising obstructive sleep apnoea (OSA) and central sleep apnoea (CSA), is associated with increased morbidity, mortality, and sleep disruption. We hypothesised that treating sleep-disordered breathing with a peak-flow triggered adaptive servo-ventilation (ASV) device would improve cardiovascular outcomes in patients with heart failure and reduced ejection fraction.

Methods

We conducted a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial of peak-flow triggered ASV in patients aged 18 years or older with heart failure and reduced ejection fraction (left ventricular ejection fraction ≤45%) who were stabilised on optimal medical therapy with co-existing sleep-disordered breathing (apnoea-hypopnoea index [AHI] ≥15 events/h of sleep), with concealed allocation and blinded outcome assessments. The trial was carried out at 49 hospitals in nine countries. Sleep-disordered breathing was stratified into predominantly OSA with an Epworth Sleepiness Scale score of 10 or lower or predominantly CSA. Participants were randomly assigned to standard optimal treatment alone or standard optimal treatment with the addition of ASV (1:1), stratified by study site and sleep apnoea type (ie, CSA or OSA), with permuted blocks of sizes 4 and 6 in random order. Clinical evaluations were performed and Minnesota Living with Heart Failure Questionnaire, Epworth Sleepiness Scale, and New York Heart Association class were assessed at months 1, 3, and 6 following randomisation and every 6 months thereafter to a maximum of 5 years. The primary endpoint was the cumulative incidence of the composite of all-cause mortality, first admission to hospital for a cardiovascular reason, new onset atrial fibrillation or flutter, and delivery of an appropriate cardioverter-defibrillator shock. All-cause mortality was a secondary endpoint. Analysis for the primary outcome was done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT01128816) and the International Standard Randomised Controlled Trial Number Register (ISRCTN67500535), and the trial is complete.

Findings

The first and last enrolments were Sept 22, 2010, and March 20, 2021. Enrolments terminated prematurely due to COVID-19-related restrictions. 1127 patients were screened, of whom 731 (65%) patients were randomly assigned to receive standard care (n=375; mean AHI 42·8 events per h of sleep [SD 20·9]) or standard care plus ASV (n=356; 43·3 events per h of sleep [20·5]). Follow-up of all patients ended at the latest on June 15, 2021, when the trial was terminated prematurely due to a recall of the ASV device due to potential disintegration of the motor sound-abatement material. Over the course of the trial, 41 (6%) of participants withdrew consent and 34 (5%) were lost to follow-up. In the ASV group, the mean AHI decreased to 2·8–3·7 events per h over the course of the trial, with associated improvements in sleep quality assessed 1 month following randomisation. Over a mean follow-up period of 3·6 years (SD 1·6), ASV had no effect on the primary composite outcome (180 events in the control group vs 166 in the ASV group; hazard ratio [HR] 0·95, 95% CI 0·77–1·18; p=0·67) or the secondary endpoint of all-cause mortality (88 deaths in the control group vs. 76 in the ASV group; 0·89, 0·66–1·21; p=0·47). For patients with OSA, the HR for all-cause mortality was 1·00 (0·68–1·46; p=0·98) and for CSA was 0·74 (0·44–1·23; p=0·25). No safety issue related to ASV use was identified.

Interpretation

In patients with heart failure and reduced ejection fraction and sleep-disordered breathing, ASV had no effect on the primary composite outcome or mortality but eliminated sleep-disordered breathing safely.

Funding

Canadian Institutes of Health Research and Philips RS North America.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yansiyi发布了新的文献求助10
刚刚
xiaofengyyy完成签到,获得积分10
1秒前
1111发布了新的文献求助10
1秒前
Orange的应助被xhy777采纳,获得10
1秒前
xixihaha完成签到,获得积分10
1秒前
王德荣完成签到,获得积分10
2秒前
不安寒风完成签到,获得积分10
2秒前
Su完成签到 ,获得积分10
3秒前
脑洞疼的应助被Lee采纳,获得10
3秒前
电风扇完成签到,获得积分10
4秒前
zxcharm完成签到,获得积分0
4秒前
Jared发布了新的文献求助10
4秒前
我是谁的应助被哈哈镜阿姐采纳,获得30
5秒前
6秒前
Yob完成签到,获得积分10
6秒前
乐乐的应助被zyy采纳,获得30
7秒前
规划计划完成签到 ,获得积分10
7秒前
科研通AI6.2的应助被tjl采纳,获得10
8秒前
邱燈完成签到,获得积分10
9秒前
SciGPT的应助被外向的大狮子采纳,获得10
10秒前
10秒前
天天快乐的应助被6666采纳,获得10
10秒前
伶俐绿柏完成签到,获得积分10
11秒前
11秒前
传奇3的应助被JF123_采纳,获得10
11秒前
Owen的应助被yansiyi采纳,获得20
12秒前
eerrtt完成签到,获得积分10
13秒前
13秒前
13秒前
松下完成签到,获得积分10
13秒前
14秒前
打打的应助被廖翰彬采纳,获得10
14秒前
14秒前
Qiiiyoung完成签到,获得积分10
14秒前
张远幸发布了新的文献求助10
15秒前
15秒前
15秒前
peng完成签到,获得积分10
15秒前
16秒前
缺粥发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820